Lung Squamous Cell Carcinoma Stage IV Clinical Trial
Official title:
A Survival Observational Study in Patients With Advanced IIIB-IV Squamous Cell Lung Cancer Receiving PD-1 Combination With Chemotherapy (RESPONSE)
This is a multi-center, open-label, non-interventional, retrospective registry study, with no
pre-set statistical assumptions and will not intervene subject's clinical treatment or
clinical management.
In the study, the clinical data of the subjects will be retrospectively collected from the
electronic health records (EHR) of each research center. The clinical information will be
based on the actual medical records of the cases. After the retrospective study time (June
30, 2020), patients will be followed for one-year and two-year survival. Clinical treatment
and management will be based on local clinical practices and regulations. This study will
record the actual diagnosis and treatment, and will not interfere with any clinical decision.
After subject-out, patients will be followed for one-year and two-year survivals, thus the
follow-up consent will be exempted. All patients receiving PD-1 monoclonal antibody in
combination with chemotherapy will be visited during the entire study period. At the end of
study, investigator will check up on the conditions of patients who withdraw from the study.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01115790 -
A Phase 1 Study in Participants With Advanced Cancer
|
Phase 1 | |
| Terminated |
NCT02831933 -
Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal Melanoma
|
Phase 2 |